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ABSTRACT
BACKGROUND: Adoption of palliative care approach in the management of advanced prostate cancer is important 
because of the advanced nature of the disease, long course of disease and the fact that prostate cancer predominantly 
affects the elderly people who are at greater risk of having other comorbidities. Most patients with prostate cancer 
present at an advanced stage in Radiotherapy and Oncology Department (ABUTH) requiring the use of palliative 
radiotherapy, chemotherapy, hormonal manipulations, bisphosphonates, analgesics, psychosocial, spiritual and financial 
support.
AIM: The aim was to evaluate the effect of palliative care in the management of advanced prostate cancer. The objectives 
were to determine the effect of palliative external beam radiotherapy, chemotherapy, bisphosphonates and analgesics in 
symptom control.
This study is a 9 years retrospective study of patients with advanced prostate cancer from January 2006 to December2014. 
Information was obtained from the treatment cards as well as case files.
RESULTS: Results showed that 139 patients received palliative External Beam Radiotherapy (EBRT). Commonest 
indication was pain of bone metastases seen in 84(60%) patients. Others included obstructive uropathy in 41(30%) 
patients, spinal cord compression in 8(6%) patients and bleeding in 6 (4%) patients. One hundred and eight (77.7%) patients 
received analgesics and 123 (88.5%) patients received haematinics. Bisphosphonates were administered to 34(24%) 
patients, while 26(17%) patients received chemotherapy. These various forms of treatment resulted in good symptom 
control and improved quality of life.
CONCLUSION: Palliative care plays a pivotal role in the management of advanced prostate cancer, and the earlier it is 
commenced, the better the outcome for the patients.
Original Article 
INTRODUCTION
raditionally, advanced prostate cancer 
Twas considered as disease that had metastasized beyond the prostate, to 
the surrounding tissue, pelvic lymph nodes 
1-2and considered incurable.  Current evidence 
indicates that patients with signicant risk of 
progressive disease, and patients with cancer 
outside the capsule with disease stage as low 
3
as T3 N0 M0 have advanced disease.
Worldwide, prostate cancer is the second 
4
commonest malignancy in men.  Studies in 
Nigeria revealed a rising incidence of prostate 
5-6cancer.  This can be attributed to increased 
awareness and improved screening methods. 
Most patients (90%) present at an advanced 
stage due to ignorance, poverty, inadequate 
diagnostic facility and absent screening. 
Prostate specic antigen (PSA) blood test and 
yearly digital rectal examination (DRE), 
beginning at age 50 should be offered to men 
who are at average risk of prostate cancer. 
Some also present with other co morbidities, 
necessitating the adoption of palliative care as 
7an important management approach.  This 
requires the use of palliative radiotherapy, 
palliative surgery, hormonal manipulations, 
chemotherapy,  bisphosphonates and 
analgesics, aimed at improving quality of 
8life.
We review our experience in palliative care of 
advanced prostate cancer over a 9 year period 
to highlight the effect of palliative EBRT, 
chemotherapy bisphosphonates  and 
analgesics in symptom control.
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PATIENTS AND METHODS 
This was a nine year retrospective study of 
advanced prostate cancer patients from 
January 2006 to December 2014. Information 
was obtained from patient's treatment card 
and folders. Data was analyzed using SPSS 
version 20.
RESULTS
Hundred patients were studied from 2006 to 
2014. The highest number of patients was 
seen in 2010 (Table 1).  The age ranged from 50 
years to 90 years with median age of 60 years 
(Figure 1). Commonest histological type was 
adenocarcinoma seen in 137(98%) patients. 
Leiomyosarcoma occurred in a (0.7%) 55 year 
old patient and a (0.7%) case of urothelial 
carcinoma was recorded (Table 2). Eighty-
four (60.4%) patients had Gleason score 
between 8 and 10, 38(27.4%) patients had 
Gleason score between 4 and 6, while 
15(10.8%) patients had Gleason score of 7 
(Table 3). Prostate specic antigen (PSA) 
value between 0-10ng/ml were seen in 
42(30.2%) patients, 47(33.8%) patients had 
PSA value between 11ng/ml – 20ng/ml, 
25(18%) patients had between 21ng/ml-
100ng/ml while another 25(18%) patients had 
PSA value greater   than 100ng/ml. (Figure 2).
Pain of bone metastasis was seen in 84 (60%) 
patients followed by urinary obstruction in 41 
(30%) patients, spinal cord compression in 8 
(6%) patients, bleeding in 6 (4%) patients were 
the commonest symptoms seen in our 
department (Figure 3).
Duration of symptoms ranged from 6months 
to 3 years. Pelvic bone was the commonest site 
of metastasis seen in 54(39%) patients, 
followed by the lumbar bone in 32 (23%) 
patients(Table 4).Other sites of bony 
metastases were thoracic 17 (12%) patients, 
cervical 11(8%) patients sacral 11(8%), 
humerus 8 (6) patients  and femur 6 (4%) 
patients. Thirty four (24%) patients received 
bisphosphonates. Goserelin (Zoladex) was 
administered to 17(12%) patients. Twenty 
four (17%) patients received chemotherapy 
using intravenous docetaxel75mg/m2and 
prednisolone once every 3weeks which was 
repeated for up to 6 to 10 cycles as tolerated. 
The case of urothelial carcinoma received 
intravenous Cisplatin 75mg/m2 and 5 
uorouraci l  500mg/m2 combination 
c h e m o t h e r a p y  w h i l e  t h e  c a s e  o f 
leiomyosarcoma received Vincristine 
2mg/m2 , Adriamycin 50mg/m2 and 
Cyclophosphomide 500mg/m2(Table 5). 
Oral morphine (10mg tds) was administered 
to 38(27%) patients and 70(50.4%) patients 
received non steroidalanti-inammatory 
drugs. Record of analgesic prescription was 
not found in 32(23%) patients. All the patients 
r e c e i v e d  p a l l i a t i v e  e x t e r n a l  b e a m 
radiotherapy (EBRT). The commonest site of 
metastasis requiring palliative external beam 
radiotherapy was the pelvic region. 15 Gray 
(Gy) in 5 fractions (#) over1week was the 
commonest prescribed dose which was 
followed by 8Gy in single fraction (table 6).
Sixty patients (43%) received nancial 
support from their families and careers. 
54(39%) patients supported themselves 
nancially. State governments assisted 
6(4.3%) patients while ministry of health 
assisted only 1(0.7%) patient.  Public 
institutions rendered nancial aid to only 
4(2.9%) patients while religious bodies 
supported 14 (10.1%) patients nancially (Fig 
4). There was no health insurance cover for 
cancer patients during the period. Twenty 
eight (20.1%) patients beneted from spiritual 
support given mainly as part of end of life 
care. At six months follow up 28(20.1%) 
patients were referred back to their primary 
referral centers, 21(15.1%) patients were lost 
to follow up and 14 (10.1%) patients died. 
Fifty six 56(40.3%) patients had immediate 
relief of symptoms after completion of 
t reatment ,  whi le  20(14 .4%)  pat ients 
experienced symptom relief within 6 months 
of treatment (Table 7).
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Table2: Table showing the tumor 
histological types






Table 3: Gleason score





4 – 6 38 27.4
7 15 10.8
8 – 10 84 60.4
TOTAL 139 100
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Table 4: Table showing Patients metastatic 
site
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Table 5: Table showing Chemotherapy 










Cisplastin + 5FU 1 3.8
TOTAL 26 100









8Gy in 1# 42 30.2
20Gy in 5# 21 15.1
30Gy in 10# 19 13.6
50Gy in 25# 14 10.1
Total 139 100










Table 7: Table showing EBRT treatment 









Pain relief after 6 
months
20 14.4
Referred back 28 20.1
Loss to follow up 21 15.1
Passed on 14 10.1
Total 139 100
DISCUSSIONS
Utilization of palliative care approach in the 
management of advanced prostate cancer 
impacts positively on the quality of life of 
these patients. Signicant pain reduction as 
well as improvement in physical, emotional 
and social functions can be achieved.
In this study, the median age of the patients 
was 60 years. Although this is earlier than that 
reported in Ibadan and Port Harcourt which 
were 71.6 years and 71.4 years respectively 
but it still conrms that prostate cancer is a 
6-7 
disease that occurs with old age. These 
patients may be prone to other co morbidities 
as a result of advancing age. 
Levels of prostate specic antigen in the blood 
are signicantly elevated in prostate cancer. 
There is no clear “cut-off” level for normality, 
though ˃4ng/ml in the blood is associated 
with a 20% risk of cancer of the prostate. The 
rate of fall in the treatment is a good 
prognostic indicator of response.
The pelvic region was the commonest 
metastatic site followed by the lumbar spine. 
This does not correspond with what was 
found in advanced countries where the 
lumbar vertebrae was the commonest, 
9
followed by sternum, pelvic, ribs and femur.  
However some studies also reported the 
10pelvis as the commonest metastatic site.
Fifteen Gray (15Gy) in 5# over one week was 
the most frequently prescribed dose as 
reported in this study. However, studies 
showed that 8Gy in single fraction a form of 
short course treatment is also effective, 
reduces cost and stress on the patient and care 
givers. However, studies found that re-
treatment is commoner with 8Gy in single 
1 1
fract ion. Commonest  indicat ion for 
palliative radiotherapy in our setting was 
pain from bony metastasis (60%). This is in 
agreement with similar studies which 
recorded pain from bony metastasis highest 
12
in their list.
Other indications included obstructive 
symptoms 30%, cord compression 6% and 
bleeding 4%.
4
Chemotherapy agent that was used in this 
study was docetaxel which was given 
intravenously to 24 patients. A case of 
leiomyosarcoma in a 55 year old man received 
VAC regimen and the only case of urothelial 
carcinoma received Cisplatin and 5FU 
combination chemotherapy.
The use of intravenous docetaxel with 
prednisolone is the practice globally 
supported by the landmark clinical trial (TAX 
13327 study).
The quality of life improved, and pain was 
reduced, decreasing the need for analgesics 
which was among the outcome that was seen 
in the TAX 327 study. The use of analgesics as 
symptom relief was also documented in a 
14study by Adenipekun et al in Ibadan.  
However this comes with an increased cost.
24 patients beneted from the administration 
of bisphosphonates. Intravenous Zoledronic 
acid 4mg every 3 weeks was the only type 
prescribed according to this study. The aim 
was to reduce skeletal related events and 
improve quality of life which is supported by 
15different studies.
Pain relief was also achieved using the World 
Health Organization (WHO) step ladder 
principle. Most patients in this study had 
moderate to severe pain for which weak 
opiods such as tramal and also non-
steroidalanti-nammatory drugs (diclofenac) 
were given. Thirty eight (27.3%) patients 
received strong opiods(Morphine) which was 
16-17
able to reduce their pain signicantly.
Other forms of palliative care services 
including spiritual care were rendered by the 
palliative care team in Radiotherapy and 
Oncology Department of ABUTH. Seventy 
(50.4%) patients benetted as well as their 
family members. Patients who benetted 
from palliative care were more stable 
psychologically and their family members 
were more satised. Studies have supported 
palliative care as a means of improving the 
quality of life of the patients and their care 
18givers.
Immediate pain relief was recorded in 56 
patients (40.3%) after receiving palliative 
EBRT treatment. Other symptoms such as 
bleeding, urinary obstruction, spinal cord 
compression were signicantly reduced. 
However, the degree of pain, symptomatic 
relief, duration of relief of pain and other 
symptoms which a prospective study 
considering patients reported outcome will 
discover is ongoing in our center.
CONCLUSION
The approach to treatment is inuenced by 
age, histological grade, co-morbidities and 
PSA level.
Palliative care approach is effective in the 
symptomatic control of patients with 
advanced prostate  cancer .  A mult i -
disciplinary team approach to treatment and 
other modalities such as EBRT chemotherapy 
will reduce the level of dependency on 
12analgesics use among others.  The side effects 
of different forms of treatment are to be 
considered in determining appropriate 
management.
There is need for awareness and more 
research efforts which will ultimately result 
in improving the quality of life of these 
patients and their care givers. The advanced 
prostate cancer is not usually curable, and a 
substantial fraction of the patient will 
eventually die of their cancer. Median 
survival is usually 1to 3 years. Men with 
advanced prostate carcinoma should be 
encouraged to participate in clinical trials and 
referred early to a clinical oncologist for a 
better outcome. 
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